查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1427229

全球奈米医学市场规模、份额、成长分析，按应用范围、适应症范围划分 - 2023-2030 年产业预测

Global Nanomedicine Market Size, Share, Growth Analysis, By Application Scope(Therapeutics, In-vitro Diagnostics), By Indication Scope(Clinical Oncology, Infectious Diseases) - Industry Forecast 2023-2030
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

在预测期（2024-2031年），全球奈米药物市场规模预计将从2023年的1912.7亿美元增加至2031年的4,040.8亿美元，复合年增长率为9.8%，2022年为1,742亿美元。

奈米医学市场的主要目标是开拓创新的解决方案来解决未满足的医疗需求并改善患者的治疗结果。与传统医疗方法相比，奈米医学具有多种优势，包括卓越的药物传递、更高的生物有效性、最小化的副作用和标靶治疗。其目的是利用奈米技术开发更有效率、更精确、针对个别患者量身定制的先进医疗照护。全球奈米医学市场的成长受到多种驱动因素​​的推动，例如奈米技术的进步为奈米尺度的精确操作提供了新的工具和技术，为新的医疗应用开闢了可能性。然而，奈米医学市场也面临挑战，主要障碍之一是开发和製造过程复杂且成本高昂。遇到的一个主要挑战是奈米医学产品的规模化和商业化。儘管研究和临床前阶段通常会产生有希望的结果，但将这些发现转化为可扩展的、具有成本效益的商业产品仍存在重大障碍。儘管面临挑战，奈米医学市场仍存在巨大的成长和创新机会。随着奈米技术研究的进步，开发新的治疗方法和诊断方法具有巨大的潜力。奈米医学为靶向药物传输系统、个人化医疗和非侵入性成像技术提供了机会。为了彻底改变医疗保健领域，全球奈米医学市场正在利用奈米技术的潜力来改善诊断、标靶治疗和个人化医疗。该市场是由奈米技术的进步以及慢性病患病率的增加所推动的。然而，必须解决高成本、监管复杂性和扩充性等挑战。然而，这个市场为创新解决方案提供了巨大的机会，这些解决方案可以改变医疗保健服务并改善患者的治疗结果。

使用自上而下和自下而上的方法来估计和检验全球奈米医学市场的规模，并估计其他各个相关子市场的规模。用于估计市场规模的调查方法包括以下详细资讯：用于确定市场主要企业的二次研究，用于确定各自区域市场占有率的主要和二次研究。整个过程包括研究主要企业的年度报告和财务报告，以及广泛的采访，以获取首席执行官、副总裁、董事和营销负责人等行业领导者的关键见解。马苏。所有股份比率和细分均使用二手资讯确定并使用主要资讯检验。本研究涵盖的所有可能影响市场的参数都经过广泛深入的考察、初步研究检验和分析，以获得最终的定量和定性资料。

奈米医学全球细分市场分析

全球奈米医学市场根据应用范围、适应症范围和地区进行细分。依应用范围划分，市场分为治疗药物、体外诊断、药物传输、体内成像和植入。依适应症范围划分，市场分为临床肿瘤学、感染疾病、临床心臟病学、整形外科等。依地区划分，分为北美、欧洲、亚太地区、中东/非洲、拉丁美洲。

全球奈米医学市场的驱动因素

癌症、心血管疾病和糖尿病等慢性疾病的盛行率不断上升是奈米医学市场的主要驱动因素。奈米医学提供有针对性的个人化治疗，有可能增强治疗效果并改善患者的生活品质。

奈米技术的不断进步为创新奈米医学解决方案铺平了道路。药物传输系统的改进、成像技术的增强和奈米级诊断工具的开发正在扩大奈米医学应用的可能性并推动市场成长。

全球奈米医药市场的限制因素

奈米医学产品的研究、开发和商业化成本高。复杂的製造流程和严格的监管要求导致奈米医学产品推向市场的成本增加，可能阻碍广泛普及。

确保奈米医学产品的安全性和生物相容性对于其成功实用化至关重要。正在进行的关于奈米颗粒对人类健康的潜在毒性和长期影响的研究使安全考虑变得更加复杂。解决这些安全问题并获得监管部门的核准对市场成长构成了挑战。

全球奈米医学市场趋势

奈米医学透过提供适合个人特定需求的药物和治疗方法来促进个人化治疗策略。个人化医疗的日益增长趋势正在推动奈米医学的普及，提供有针对性的个人化治疗选择。

一个新兴趋势是将奈米药物与免疫疗法和基因疗法等各种治疗方法结合。不同治疗方法的融合有可能提高治疗效果、克服抗药性并产生协同效应，为奈米医学应用带来新的机会。

目录

  • 执行摘要
  • 调查方法
  • 母市场分析
  • 主要市场考察
    • 技术分析
    • 价格分析
    • 供应链分析
    • 价值链分析
    • 市场生态系统
    • 智慧财产权分析
    • 贸易分析
    • Start-Ups分析
    • 原料分析
    • 创新矩阵
    • 研发线产品分析
    • 总体经济指标
    • 主要投资分析
    • 关键成功因素
    • 竞争程度
  • 市场动态及展望
    • 市场动态
      • 促进因素
      • 机会
      • 抑制因素
      • 任务
    • 监管形势
    • 波特的分析
    • 对未来中断的特殊考虑
  • 全球奈米药物市场：按应用范围划分
    • 市场概况
    • 治疗
    • 体外诊断
    • 药物输送
    • 体内影像
    • 植入
  • 全球奈米药物市场：依适应症范围划分
    • 市场概况
    • 临床肿瘤学
    • 感染疾病
    • 临床循环系统
    • 整形外科
    • 其他的
  • 全球奈米医学市场规模：按地区划分
    • 市场概况
    • 北美洲
      • 美国
      • 加拿大
    • 欧洲
      • 德国
      • 西班牙
      • 法国
      • 英国
      • 其他欧洲国家地区
    • 亚太地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 其他亚太地区
    • 拉丁美洲
      • 巴西
      • 其他拉丁美洲地区
    • 中东和非洲 (MEA)
      • 海湾合作委员会国家
      • 南非
      • 其他中东/非洲地区
  • 竞争形势
    • 前5名企业对比
    • 主要企业市场定位（2021年）
    • 主要市场参与者所采取的策略
    • 关键成功策略
    • 近期市集活动
    • 主要企业市场占有率（2021年）
  • 主要企业简介
    • Pfizer Inc.（US）
    • Novartis International AG（Switzerland）
    • Johnson & Johnson（US）
    • Merck & Co., Inc.（US）
    • Abbott Laboratories（US）
    • Teva Pharmaceutical Industries Ltd.（Israel）
    • Gilead Sciences, Inc.（US）
    • Celgene Corporation（US）
    • Amgen Inc.（US）
    • GlaxoSmithKline plc（UK）
    • AstraZeneca plc（UK）
    • Sanofi SA（France）
    • Roche Holding AG（Switzerland）
    • Eli Lilly and Company（US）
    • Bristol-Myers Squibb Company（US）
    • Biogen Inc.（US）
    • Takeda Pharmaceutical Company Limited（Japan）
    • Boehringer Ingelheim International GmbH（Germany）
    • Bayer AG（Germany）
    • Astellas Pharma Inc.（Japan）
简介目录
Product Code: SQMIG35I2200

The Global Nanomedicine Market size was valued at USD 174.20 Billion in 2022 and is expected to grow from USD 191.27 Billion in 2023 to reach USD 404.08 Billion by 2031, at a CAGR of 9.8% during the forecast period (2024-2031).

The primary objective of the nanomedicine market is to pioneer innovative solutions addressing unmet medical needs and enhancing patient outcomes. Nanomedicine brings various advantages over traditional medical approaches, including superior drug delivery, heightened bioavailability, minimized side effects, and targeted therapies. The aim is to harness nanotechnology for the development of advanced medical treatments that are more efficient, precise, and tailored to individual patients. Several driving factors contribute to the global nanomedicine market's growth, such as advancements in nanotechnology providing new tools and techniques for precise manipulation at the nanoscale, thus opening up possibilities for novel medical applications. However, the nanomedicine market also faces challenges, with one key obstacle being the complex and costly nature of its development and manufacturing processes. A major challenge encountered is the scale-up and commercialization of nanomedicine products. While promising results are often attained in research and preclinical stages, translating these findings into scalable and cost-effective commercial products presents significant hurdles. Despite challenges, the nanomedicine market holds substantial opportunities for growth and innovation. As nanotechnology research advances, there is immense potential for the development of new therapeutic approaches and diagnostics. Nanomedicine provides opportunities for targeted drug delivery systems, personalized medicine, and non-invasive imaging techniques. With the aim to revolutionize healthcare, the global nanomedicine market capitalizes on nanotechnology's potential for improved diagnostics, targeted therapies, and personalized medicine. The market is driven by advancements in nanotechnology, coupled with the increasing prevalence of chronic diseases. However, challenges such as high costs, regulatory complexities, and scalability must be addressed. Nonetheless, the market presents significant opportunities for innovative solutions that can transform healthcare delivery and enhance patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nanomedicine Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nanomedicine Market Segmental Analysis

The global nanomedicine market is segmented on the basis of application scope, indication scope, and region. In terms of application scope, the market is segmented into therapeutics, in-vitro diagnostics, drug delivery, in-vivo imaging, and implants. Based on indication scope, the market is segmented into clinical oncology, infectious diseases, clinical cardiology, orthopedics, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Nanomedicine Market

The increasing prevalence of chronic diseases, including cancer, cardiovascular disorders, and diabetes, is a primary driver for the nanomedicine market. Nanomedicine provides targeted and personalized therapies that have the potential to enhance treatment outcomes and improve the quality of life for patients.

Ongoing advancements in nanotechnology have paved the way for innovative nanomedicine solutions. Improved drug delivery systems, enhanced imaging techniques, and the development of nanoscale diagnostic tools have expanded the range of possibilities for nanomedicine applications, thereby driving market growth.

Restraints in the Global Nanomedicine Market

The research, development, and commercialization of nanomedicine products incur substantial costs. The intricate manufacturing processes and stringent regulatory requirements contribute to the elevated expenses associated with bringing nanomedicine products to the market, potentially impeding widespread adoption.

Ensuring the safety and biocompatibility of nanomedicine products is imperative for their successful implementation. The ongoing study of potential toxicity and long-term effects of nanoparticles on human health adds complexity to the safety considerations. Addressing these safety concerns and obtaining regulatory approvals present challenges to the growth of the market.

Market Trends of the Global Nanomedicine Market

Nanomedicine facilitates personalized treatment strategies by administering drugs or therapies tailored to an individual's specific requirements. The increasing inclination towards personalized medicine is propelling the uptake of nanomedicine, offering targeted and individualized treatment options.

An emerging trend is the integration of nanomedicine with various treatment modalities like immunotherapy and gene therapy. The amalgamation of different therapeutic approaches has the potential to improve treatment effectiveness, overcome drug resistance, and create synergistic effects, thereby unlocking new opportunities for the applications of nanomedicine.

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
    • Regulatory Landscape
    • Porters Analysis
      • Competitive rivalry
      • Threat of Substitute Products
      • Bargaining Power of Buyers
      • Threat of New Entrants
      • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
      • Political Impact
      • Economic Impact
      • Social Impact
      • Technical Impact
      • Environmental Impact
      • Legal Impact
  • Global Nanomedicine Market by Application Scope
    • Market Overview
    • Therapeutics
    • In-vitro Diagnostics
    • Drug Delivery
    • In-vivo Imaging
    • and Implants
  • Global Nanomedicine Market by Indication Scope
    • Market Overview
    • Clinical Oncology
    • Infectious Diseases
    • Clinical Cardiology
    • Orthopedics
    • and Others
  • Global Nanomedicine Market Size by Region
    • Market Overview
    • North America
      • USA
      • Canada
    • Europe
      • Germany
      • Spain
      • France
      • UK
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia-Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • GCC Countries
      • South Africa
      • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
      • By Development
      • By Company
      • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Pfizer Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Novartis International AG (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Johnson & Johnson (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Merck & Co., Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Abbott Laboratories (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Teva Pharmaceutical Industries Ltd. (Israel)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Gilead Sciences, Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Celgene Corporation (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Amgen Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • GlaxoSmithKline plc (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • AstraZeneca plc (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Sanofi S.A. (France)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Roche Holding AG (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Eli Lilly and Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bristol-Myers Squibb Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Biogen Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Takeda Pharmaceutical Company Limited (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Boehringer Ingelheim International GmbH (Germany)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bayer AG (Germany)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Astellas Pharma Inc. (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments